RE:RE:Which way to play Tau? KLSE or DC.AAgreed.
There is a very large unmet need for Alzheimer’s disease (AD) therapies. We have an aging population thats living longer so AD keeps becoming a bigger burden on society.
With 55 million people affected, the WHO considers AD to be a disease with public priority as estimates are 150 million people by 2050.
Doctors currently have cholinesterase inhibitors for Aβ plaques but what about tau tangles?
Is there a pill with minimal side effects? The FDA has to balance delaying this medication and asking for more efficacy data. The issues are around how to design the placebo as urine discoloration is a side effect of TauRx.
The 2 year data makes a very compelling case for TauRx
"From the data shared today, participants at the early stage of AD receiving HMTM 16 mg/day remained significantly above baseline to 18 months and only returned to baseline values after 24 months. Within this subgroup, progression of symptoms to the dementia stage of the disease was significantly less than in the control group. Additionally, further analysis of this subgroup shows that the control group declined significantly below their baseline despite the switch to 16 mg/day after 12 months in the open label phase (p=0.0308 for the observed cases difference in ADAS-Cog13, being a more accurate measure for early disease)."
source https://taurx.com/news-insights/two-year-sustained-cognitive-benefits-of-hydromethylthionine-mesylate-hmtm-indicated-by-taurxs-lucidity-trial
Again the FDA has to balance the multi year delay against the immediate benefits which the patients in trial got with minimal side effects.